Trial Profile

A Phase I/II Study Of The Efficacy,Safety and Pharmacokinetics Of Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Alopecia Areata

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gecaxitinib hydrochloride (Primary)
Indications Alopecia areata
Focus Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

04 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
04 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
04 Mar 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com